Your browser doesn't support javascript.
Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.
Di Stefano, Leon; Ogburn, Elizabeth L; Ram, Malathi; Scharfstein, Daniel O; Li, Tianjing; Khanal, Preeti; Baksh, Sheriza N; McBee, Nichol; Gruber, Joshua; Gildea, Marianne R; Clark, Megan R; Goldenberg, Neil A; Bennani, Yussef; Brown, Samuel M; Buckel, Whitney R; Clement, Meredith E; Mulligan, Mark J; O'Halloran, Jane A; Rauseo, Adriana M; Self, Wesley H; Semler, Matthew W; Seto, Todd; Stout, Jason E; Ulrich, Robert J; Victory, Jennifer; Bierer, Barbara E; Hanley, Daniel F; Freilich, Daniel.
  • Di Stefano L; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Ogburn EL; Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Ram M; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Scharfstein DO; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Li T; Division of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, United States of America.
  • Khanal P; University of Colorado Denver, Anschutz Medical Campus, Denver, Colorado, United States of America.
  • Baksh SN; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • McBee N; Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
  • Gruber J; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Gildea MR; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Clark MR; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Goldenberg NA; Division of Brain Injury Outcomes, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Bennani Y; Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Brown SM; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
  • Buckel WR; Johns Hopkins All Children's Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States of America.
  • Clement ME; Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
  • Mulligan MJ; University Medical Center, New Orleans, New Orleans, Louisiana, United States of America.
  • O'Halloran JA; Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, Murray, Utah, United States of America.
  • Rauseo AM; University of Utah, Salt Lake City, Utah, United States of America.
  • Self WH; Pharmacy Services, Intermountain Healthcare, Murray, Utah, United States of America.
  • Semler MW; Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
  • Seto T; University Medical Center, New Orleans, New Orleans, Louisiana, United States of America.
  • Stout JE; Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine, New York, New York, United States of America.
  • Ulrich RJ; Vaccine Center, New York University Grossman School of Medicine, New York, New York, United States of America.
  • Victory J; Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, United States of America.
  • Bierer BE; Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, United States of America.
  • Hanley DF; Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Freilich D; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
PLoS One ; 17(9): e0273526, 2022.
Article in English | MEDLINE | ID: covidwho-2054327
ABSTRACT

BACKGROUND:

Results from observational studies and randomized clinical trials (RCTs) have led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective for COVID-19 prevention or treatment. Pooling individual participant data, including unanalyzed data from trials terminated early, enables more detailed investigation of the efficacy and safety of HCQ/CQ among subgroups of hospitalized patients.

METHODS:

We searched ClinicalTrials.gov in May and June 2020 for US-based RCTs evaluating HCQ/CQ in hospitalized COVID-19 patients in which the outcomes defined in this study were recorded or could be extrapolated. The primary outcome was a 7-point ordinal scale measured between day 28 and 35 post enrollment; comparisons used proportional odds ratios. Harmonized de-identified data were collected via a common template spreadsheet sent to each principal investigator. The data were analyzed by fitting a prespecified Bayesian ordinal regression model and standardizing the resulting predictions.

RESULTS:

Eight of 19 trials met eligibility criteria and agreed to participate. Patient-level data were available from 770 participants (412 HCQ/CQ vs 358 control). Baseline characteristics were similar between groups. We did not find evidence of a difference in COVID-19 ordinal scores between days 28 and 35 post-enrollment in the pooled patient population (odds ratio, 0.97; 95% credible interval, 0.76-1.24; higher favors HCQ/CQ), and found no convincing evidence of meaningful treatment effect heterogeneity among prespecified subgroups. Adverse event and serious adverse event rates were numerically higher with HCQ/CQ vs control (0.39 vs 0.29 and 0.13 vs 0.09 per patient, respectively).

CONCLUSIONS:

The findings of this individual participant data meta-analysis reinforce those of individual RCTs that HCQ/CQ is not efficacious for treatment of COVID-19 in hospitalized patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0273526

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hydroxychloroquine Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0273526